ICU Medical, Inc. is a San Clemente, California-based company with global operations that develops, manufactures, and sells medical technologies used in vascular therapy, oncology, and critical care applications. ICU Medical's products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical's product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems. ICU Medical's products are designed to prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. In addition, the company's IV medication compounding and delivery products are designed to improve medication and dosing accuracy and improve clinical workflows. ICU Medical has been named one of the 100 Most Trustworthy Companies in America by Forbes Magazine. History The company was founded in 1984 by George "Doc" Lopez, MD who developed a product known as the ClickLock to better secure IV lines after he lost a patient due to an accidental disconnect. The ClickLock consisted of a protected needle and locking housing that prevented health care workers from being accidentally stuck by the I.V. needles. In 2006, ICU Medical introduced its first products for oncology. The ChemoClave system from ICU Medical is a closed system transfer device (CSTD) that allows pharmacists and nurses to safely mix and administer hazardous drugs used to treat cancer patients without exposing themselves to these drugs. ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira in 2009 following a four-year business arrangement in which ICU acted as the manufacturer of the Hospira critical care product line. The acquisition allowed ICU to obtain new manufacturing space in Salt Lake City, Utah, while it also broadened the company's footprint in the hospital marketplace with products designed for use in high acuity clinical settings like the operating room and intensive care unit. With the February 2017 acquisition of the Hospira Infusion Systems business from Pfizer, ICU Medical became one of the leading pure-play infusion companies. Products Infusion therapy Over 90% of hospitalized patients receive some form of IV therapy during their stay. As a result, infusion devices must be safe, reliable, and cost-effective. ICU Medical's infusion therapy products include a line of needle-free IV connectors that provide significant clinical advantage over other devices, along with a range